GWSA
NTLA icon

Global Wealth Strategies & Associates’s Intellia Therapeutics NTLA Stock Holding History

Global Wealth Strategies & Associates’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$2.06K – 416
2024
Q3 		$2.06K Hold
100
– – ﹤0.01% 295
2024
Q2 		$2.24K Hold
100
– – ﹤0.01% 265
2024
Q1 		$2.75K Buy
+100
New +$2.78K ﹤0.01% 267

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Global Wealth Strategies & Associates's NTLA Position: Q4 2024 in Review

Global Wealth Strategies & Associates sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 100 shares — an estimated $2.06K sold.

Global Wealth Strategies & Associates first reported a position in NTLA in Q1 2024 and held it in 3 quarters. The position peaked at $2.75K in Q1 2024. 294 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Global Wealth Strategies & Associates reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Global Wealth Strategies & Associates sold 100 Intellia Therapeutics shares in Q4 2024, an estimated $2.06K.
  • Global Wealth Strategies & Associates first reported a position in Intellia Therapeutics in Q1 2024 and held it in 3 quarters.
  • Global Wealth Strategies & Associates's Intellia Therapeutics position peaked at $2.75K in Q1 2024.
  • 294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Global Wealth Strategies & Associates's 13F filing for Q4 2024, filed 2 Jan 2025.